Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2Lymphoid 1Dermatologic 1

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Brain Neoplasms 1

Interventions

Temozolomide 171Bevacizumab 106Radiotherapy 87Radiation 38Cyclophosphamide 38Etoposide 34Carboplatin 34Magnetic Resonance Spectroscopy 32Irinotecan 32Radiosurgery 27Vincristine 25pembrolizumab 24Everolimus 23Cisplatin 23Nivolumab 22Radiotherapy, Intensity-Modulated 19Isotretinoin 19Filgrastim 19Erlotinib Hydrochloride 19Topotecan 18Lomustine 17Vorinostat 16Doxorubicin 16Granulocyte Colony-Stimulating Factor 15sargramostim 14antineoplaston A10 13Radiotherapy, Conformal 13antineoplaston AS 2-1 12Granulocyte-Macrophage Colony-Stimulating Factor 12dinutuximab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × O(6)-benzylguanine × CNS × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00275002 2022-02-11

O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors

National Cancer Institute (NCI)

Phase 2 Completed
41 enrolled 9 charts
CNS

Central Nervous System Neoplasms

NCT00436436 2017-03-28

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 10 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡